The Alliance for mRNA Medicines (AMM) brings together senior executives and top decision-makers in the mRNA industry to advance pioneering research into vaccines and therapies for patients. The annual meeting, AMM ASCENT (Advancements in mRNA Science, Commercialization, Education, and Novel Technologies), features one-on-one partnering opportunities for companies and investors, dedicated networking, keynotes and fireside chats featuring KOLs and industry visionaries, as well as engaging plenary and panel discussions among biotech, pharma, and academic leaders. Our meeting this year is in collaboration with the Society for RNA Therapeutics.

Call for Abstracts

As part of this collaboration, AMM and SRT are accepting submissions for oral or poster presentations for two scientific sessions:

• Translational Research in RNA Therapeutics
• Innovation in RNA Therapeutics and Delivery

Submit your abstract by August 1 through this form.

Call for Company Presentations

The Alliance for mRNA Medicines is now accepting applications from companies interested in presenting at the ASCENT conference October 28-30, 2026. The meeting features presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of RNA medicine, including protein replacement, gene editing and cell engineering strategies, immunotherapies and vaccines.

If your company is interested in giving a 15-minute in-person presentation at this year’s meeting, please note the required criteria and complete the application using the link below:

AMM ASCENT Company Presentation Application

*Applying to presenting does not guarantee your company a presentation slot. There are a limited number of presentation spots available.

Presentation Format

Company presentations will be delivered live in the main ballroom in Coronado, CA during designated company presentation slots.

Deadline to Submit

All presentation requests must be received online by August 15, 2026 to be considered. Applicants will be notified if their company has been selected to present by September 1, 2026.

Selection Criteria

Company MUST be an AMM member in good standing or an ASCENT conference sponsor at the silver level or higher. Non-members interested in joining the organization should contact our Membership Team at contact@mrnamedicines.org for further details.

CEO or company C-Level executive MUST be available to present. Should a C-level executive not be available in the end, the presentation spot will be given to another company on the waitlist.

Priority selection is given to public and late-stage, private therapeutic developers as well as enabling technology companies. Service and tools providers are still able to apply and will be given consideration if space allows.

Presentation Cost

There is NO FEE to present at this meeting. However, presenters and additional company attendees are required to register and pay to attend the conference.

Benefits of Presenting

• Opportunity to feature your company in front of top executives in the RNA medicines field
• Opens the door for potential funding and partnership opportunities and deals
• Extensive exposure to all major industry players including big pharma, large biotech, investors, and major research institutions and foundations